Hormone-free option
Safety focused
Women’s Health Clinic FAQ
Who is not a good candidate for intimate polynucleotides?
Intimate polynucleotides are non-hormonal biostimulatory treatments used in some clinics for vulvovaginal tissue quality. The important first step is confirming the symptom cause, not choosing an injectable by name.
Direct answer
A person may not be a good candidate for intimate polynucleotides if they have active infection, unexplained bleeding, pregnancy, breastfeeding, recent pelvic surgery, severe fish allergy, active vulval skin disease, severe pelvic pain, immunosuppression, significant bleeding risk or unrealistic expectations. Cancer survivors and people with complex GSM may need specialist input. Some patients need GP, gynaecology, dermatology, oncology or pelvic-floor review before any elective intimate injectable.
Your clinician should review symptoms, medical history, allergies, medicines, cancer history where relevant, alternatives, expected benefits, limitations and aftercare before deciding whether treatment fits.
Educational only. Suitability must be confirmed after consultation and assessment. Results vary. Not a cure.
At a glance
These are the main points to understand before deciding whether intimate polynucleotides are suitable.
Polynucleotides at a glance
Non-hormonal biostimulation
Allergies to fish/salmon DNA.
Allergies to fish/salmon DNA.
Pregnancy, breastfeeding, or IVF.
Pregnancy, breastfeeding, or IVF.
Active infections (herpes, thrush, etc.).
Active infections (herpes, thrush, etc.).
Autoimmune or immunosuppressive conditions.
Autoimmune or immunosuppressive conditions.
Important safety note
Anaphylactic Risk: An undisclosed allergy to fish or fish DNA could trigger hypersensitivity or anaphylaxis.
Allergy
Evidence
Aftercare
Alternatives
Detailed answer
Reasons to defer or avoid
Infection, bleeding, pregnancy, severe fish allergy, recent surgery, unclear diagnosis and complex medical history may rule treatment out.
Referral may come first
Some patients need specialist review before any elective intimate injectable.
Evidence
Symptoms
Alternatives
What it means
Biocompatibility vs. Source: While highly purified, the extraction from salmon/trout sperm DNA means absolute exclusion for fish-allergic patients.
Why symptoms matter
Regeneration vs. Augmentation: Clinically, polynucleotides are bio-stimulators, not fillers. They rely on the patient's own cellular response.
Evidence limits
Evidence is encouraging in selected areas, but intimate-use claims should remain cautious and assessment-led.
Treatment fit
Post-Treatment Restrictions: Patients must abstain from sexual intimacy, strenuous exercise, saunas, and hot baths for 48 to 72 hours post-treatment.
What this means in practice
Post-Treatment Restrictions: Patients must abstain from sexual intimacy, strenuous exercise, saunas, and hot baths for 48 to 72 hours post-treatment.
Gradual Results: Polynucleotides work at a cellular level to stimulate fibroblasts and collagen; results take a few weeks to become noticeable, peaking over 3 to 6 months.
Patient safety
Why diagnosis comes first
Many intimate symptoms overlap. The right treatment depends on whether the issue is GSM, infection, vulval skin disease, scarring, pelvic-floor guarding, medication effect or another cause.
It checks the cause
Fish-derived product source makes allergy history a practical part of candidate screening.
It protects safety
Anaphylactic Risk: An undisclosed allergy to fish or fish DNA could trigger hypersensitivity or anaphylaxis.
It reviews alternatives
Moisturisers, lubricants, local ooestrogen, pelvic-floor care or specialist review may be more appropriate first.
It sets expectations
Polynucleotides are gradual tissue-support treatments, not instant resolves or promised outcomes.
Non-hormonal does not mean automatic
A hormone-free option may still be unsuitable if there is infection, unexplained bleeding, pregnancy, recent surgery, severe fish allergy or unclear pelvic pain.
Good care explains product source, treatment route, alternatives, limits, aftercare and when another medical pathway is safer.
Considerations
What to consider
Treatment planning should include diagnosis, symptom pattern, allergy risk, medicines, consent, realistic timelines and aftercare.
Consultation priorities
A consultation should review symptoms, medical history, fish allergy, infection risk, bleeding risk, pregnancy status, expectations and alternatives.
Consent
Aftercare
Review
Before treatment
Thorough Screening: Begins with a comprehensive medical history consultation to rule out autoimmune conditions, allergies, or contraindicated medications.
During care
Preparation: Patients must stop NSAIDs, fish oils, and alcohol 24-48 hours prior to minimise bruising.
Aftercare
Procedure Day: Patients may need to prepare the area and expect mild discomfort.
When to reassess
If symptoms persist, worsen or do not match expectations, reassessment is safer than repeating treatment automatically.
Practical expectations
Gradual Results: Polynucleotides work at a cellular level to stimulate fibroblasts and collagen; results take a few weeks to become noticeable, peaking over 3 to 6 months.
Costs and treatment plans should be confirmed before booking; do not rely on generic package claims.
Common concerns and myths
Common misconceptions
Clear patient information should correct over-simple claims and keep expectations realistic.
Myth: polynucleotides are fillers
Reality: they are biostimulatory DNA fragments used for gradual tissue-quality support, not instant volume.
Myth: hormone-free means suitable for everyone
Reality: fish allergy, infection, bleeding, pregnancy, recent surgery and unclear pain can make treatment unsuitable.
Myth: results are promised
Reality: response varies and should be reviewed before repeating treatment.
Evidence and limits
Mechanism-of-action language should not be treated as proof of a predictable result.
Alternatives still matter
Moisturisers, local hormonal care, pelvic-floor physiotherapy, infection treatment or specialist review may be better for some patients.
Safety checklist
Safety checklist
Use these questions to decide whether treatment should be discussed, delayed or redirected.
Has the cause been assessed?
Symptoms should be reviewed in context before selecting an injectable treatment.
Are red flags absent?
Active infection, unexplained bleeding, severe pain or new vulval changes should be checked first.
Are alternatives clear?
Ask what conservative, hormonal, pelvic-floor or specialist options may be more appropriate.
Is follow-up planned?
The clinic should explain aftercare, review timing and when to seek help.
Reassuring signs
Proceeding is more reasonable when diagnosis is clear, goals are realistic, red flags are absent and aftercare is understood.
No red flags
Review plan
Reasons to pause
Pause treatment for active infection, unexplained bleeding, pregnancy, severe fish allergy, recent pelvic surgery, severe pain or changing vulval skin.
Bleeding
Infection
When to escalate
When to seek medical help
Some symptoms should be assessed before any elective intimate treatment. Use NHS 111 online
Allergy symptoms
Swelling of the lips, tongue or face, breathing difficulty, widespread hives, faintness or collapse needs urgent help.
Bleeding or new skin change
New post-menopausal bleeding, ulcers, changing white plaques, unusual discharge or visible blood in urine should be assessed.
Infection signs
Fever, pus, spreading redness, worsening swelling or feeling unwell after a procedure needs prompt advice.
Emergency symptoms
Call 999 in a life-threatening emergency, including collapse, chest pain or breathing difficulty.
Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.
Regulatory resources
Authoritative resources
These sources support assessment-led, evidence-aware patient information and help separate clinical care from promotional claims.
PubMed: PN/HA intradermal treatment for vulvovaginal atrophy
This pilot study is directly relevant to PN/HA use in vulvovaginal atrophy and supports cautious evidence-aware discussion.
NICE menopause recommendations
NICE provides UK guidance for GSM, vaginal ooestrogen, non-hormonal care and cancer-history decision-making.
NHS guidance on allergies
NHS allergy guidance supports screening and urgent escalation language for fish-derived products.
Next step
Book a clinical consultation
A consultation can confirm whether intimate polynucleotides may be suitable, whether another pathway should come first, and what realistic outcomes, risks and aftercare would look like.
▶ View Research Sources (12 Sources)
These 12 source names are selected from 24 display-ready sources, with a raw audit trail of 64 imported records. Additional reviewed material included peer-reviewed clinical papers; duplicate, low-relevance and non-clinical records were removed before display.
Educational only. This information is for education only and is not a substitute for professional medical advice, diagnosis or treatment. Results vary. Not a cure.
